Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds
Authors:
- M. Isabel CrespoMCM. Isabel Crespo
- Ferran PujolFPFerran Pujol
- Jorge BeletaJBJorge Beleta
- Teresa DoménechTDTeresa Doménech
- Montserrat MiralpeixMMMontserrat Miralpeix
- Jose M. PalaciosJPJose M. Palacios
- Ana CastroACAna Castro
- Ana MartinezAna Martinez
- 1 March 1998
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 8 (5) , 505-510
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Computer-based screening of compound databases for the identification of novel leadsDrug Discovery Today, 1996
- Chapter 8. Chronic Pulmonary Inflammation and Other Therapeutic Applications of PDE IV Inhibitors1996
- Phosphodiesterase type IV inhibitors as antiinflammatory agentsDrugs of the Future, 1995
- The Discovery of Novel, Structurally Diverse Protein Kinase C Agonists through Computer 3D-Database Pharmacophore Search. Molecular Modeling StudiesJournal of Medicinal Chemistry, 1994
- Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: additional action of the antagonistsBiochemical Pharmacology, 1994
- Chapter 19. Isozyme-Selective Phosphodiesterase Inhibitors as Antiasthmatic Agents1994
- Chapter 12. Novel Approaches to Anti-Inflammatory Agents as Therapeutics for Pulmonary Disease1993
- 3D database searching in drug designJournal of Medicinal Chemistry, 1992
- Substance P antagonistsDrugs of the Future, 1992
- Conformational freedom in 3-D databases. 1. TechniquesJournal of Chemical Information and Computer Sciences, 1990